General Information of Drug Transporter (DT)
DT ID	DTD0513 Transporter Info
Gene Name	KCNQ1
Protein Name	Voltage-gated potassium channel Kv7.1
Gene ID	3784
UniProt ID	P51787
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2237897
Site of GPD	chr11:2837316 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0378/140 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Gliclazide	Drug Info	Diabetes Mellitus	Irrelevant to the drug response in patients (compare with allele C)		[ 1]
Gliclazide	N.A.	Hypoglycemia	Allele T is not associated with response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 1]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gliclazide	N.A.	Hypoglycemia	Genotypes CT + TT are associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 1]
Genetic Polymorphism	rs163184
Site of GPD	chr11:2825839 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.6360/1258 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sitagliptin	N.A.	Angioedema	Genotype GG is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.		[ 2]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Gliclazide	N.A.	Angioedema	Genotypes GT + TT is associated with increased clinical benefit to gliclazide, glimepiride, glipizide or glyburide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.		[ 3]
Glimepiride	N.A.	Angioedema	Genotypes GT + TT is associated with increased clinical benefit to gliclazide, glimepiride, glipizide or glyburide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.		[ 3]
Glipizide	N.A.	Angioedema	Genotypes GT + TT is associated with increased clinical benefit to gliclazide, glimepiride, glipizide or glyburide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.		[ 3]
Glyburide	N.A.	Angioedema	Genotypes GT + TT is associated with increased clinical benefit to gliclazide, glimepiride, glipizide or glyburide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.		[ 3]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Sitagliptin	N.A.	Angioedema	Genotypes GG + GT is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.		[ 4]
Vildagliptin	N.A.	Angioedema	Genotypes GG + GT is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.		[ 4]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Glimepiride	N.A.	Hypoglycemia	Allele G is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 5]
Glipizide	N.A.	Hypoglycemia	Allele G is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 5]
Glyburide	N.A.	Hypoglycemia	Allele G is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 5]
Sitagliptin	N.A.	Hypoglycemia	Allele G is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 6]
Vildagliptin	N.A.	Hypoglycemia	Allele G is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 6]
Exenatide	N.A.	Hypoglycemia	Allele G is associated with decreased clinical benefit to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 7]
Genetic Polymorphism	rs2237892
Site of GPD	chr11:2818521 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.8530/1688 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Gliclazide	N.A.	Angioedema	Allele T is associated with increased clinical benefit to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 8]
Glimepiride	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 5]
Glipizide	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 5]
Glyburide	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 5]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Repaglinide	N.A.	Angioedema	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 9]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 9]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Allele C is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 10]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Genetic Polymorphism	rs2237895
Site of GPD	chr11:2835964 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>T
Minor Allele Frequency	A=0.6830/1351 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Gliclazide	N.A.	Angioedema	Allele C is associated with increased clinical benefit to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 8]
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 5]
Glipizide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 5]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 5]
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Repaglinide	N.A.	Angioedema	Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.		[ 9]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.		[ 9]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Ibrutinib	N.A.	Cardiac Rhythm Disease	Genotype AA is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes AC + CC.		[ 11]
Ibrutinib	N.A.	Cardiotoxicity	Genotype AA is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes AC + CC.		[ 11]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.		[ 13]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tacrolimus	N.A.	Diabetes Mellitus	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with cadaveric kidney graft as compared to genotype AA.		[ 12]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with cadaveric kidney graft as compared to genotype AA.		[ 12]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.		[ 9]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.		[ 12]
Genetic Polymorphism	rs163182
Site of GPD	chr11:2822986 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.6070/1201 (Global)
Genotypes CC + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Epirubicin	N.A.	Disease Progression	Genotypes CC + GG is associated with decreased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CG.		[ 13]
Fluorouracil	N.A.	Disease Progression	Genotypes CC + GG is associated with decreased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CG.		[ 13]
Oxaliplatin	N.A.	Disease Progression	Genotypes CC + GG is associated with decreased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CG.		[ 13]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ibrutinib	N.A.	Cardiac Rhythm Disease	Genotype GG is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes CC + CG.		[ 11]
Ibrutinib	N.A.	Cardiotoxicity	Genotype GG is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes CC + CG.		[ 11]
Genetic Polymorphism	rs11022922
Site of GPD	chr11:2457965 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.5270/1042 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Diarrhea	Allele C is not associated with likelihood of Diarrhea when treated with irinotecan in people with Neoplasms as compared to allele T.		[ 14]
References
1	Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients. Pharmacogenet Genomics. 2016 Apr;26(4):178-183.
2	Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis. Medicine (Baltimore). 2025 Jan 10;104(2):e41061.
3	Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 2011 Jul;17(7):CR392-6.
4	KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract. 2017 Aug;130:142-147.
5	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. Pharmacogenomics J. 2020 Dec;20(6):831-839.
6	Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors. Pharmacogenomics. 2020 Apr;21(5):317-323.
7	KCNQ1 variant rs163184 is a potential biomarker of glycemic response to exenatide. Pharmacogenomics. 2022 Apr;23(6):355-361.
8	Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. Acta Pharmacol Sin. 2017 Jan;38(1):80-89.
9	KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2012 May;39(5):462-8.
10	Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study. Pharmacogenomics. 2021 Nov;22(16):1057-1068.
11	Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity. Pharmacogenet Genomics. 2025 Apr 01;35(3):101-109.
12	KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients. Clin Transplant. 2011;25(3):E284-91.
13	Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen. Pharmacogenomics. 2015;16(9):959-70.
14	Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect. PLoS One. 2014;9(8):e105160.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.